[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-hepatocellular-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-hepatocellular-carcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100618854","a-trial-of-behavioral-intervention-on-prognostic-survival-of-patients-with-unresectable-liver-cancer-100618854",false,"NCT07337031","A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer","A Randomized Controlled Trial of Complex Behavioral Intervention on Prognostic Survival in Comprehensive Treatment of Patients With Unresectable Liver Cancer","Inclusion Criteria:\n\n1. Pathologically or radiologically confirmed primary hepatocellular carcinoma;\n2. BCLC stage B-C, initially assessed as unresectable;\n3. Age 18-75 years;\n4. ECOG performance status score 0-2;\n5. Child-Pugh classification grade A or B (\\\u003C=9 points);\n6. Normal cognitive ability, capable of understanding and following intervention protocols;\n7. Both the patient and primary caregiver can use a smartphone and the WeChat platform and are able to complete questionnaires and follow-up tasks;\n8. Voluntarily participates in the study and signs the informed consent form.\n\nExclusion Criteria:\n\n1. Presence of malignant tumors in other organs;\n2. Presence of extrahepatic metastasis;\n3. Presence of any of the following severe organic diseases in any organ:\n\n(1) Cardiovascular: NYHA class III-IV heart failure, acute coronary syndrome within the past 6 months; (2) Liver: Child-Pugh class C cirrhosis, or ALT\u002FAST \\>5 times the upper limit of normal; (3) Kidney: eGFR \\\u003C45 mL\u002Fmin\u002F1.73m\\^2 or dialysis-dependent; (4) Respiratory: respiratory failure requiring long-term oxygen therapy; (5) Hematologic: hemoglobin \\\u003C9 g\u002FdL or platelets \\\u003C75×10\\^9\u002FL; 4. History of psychiatric disorders, severe cognitive impairment, or substance abuse; 5. Previous liver transplantation or treatment for malignant liver tumors; 6. Complete thrombosis of the main portal vein; 7. Female patients who are pregnant or breastfeeding; 8. Presence of severe congenital or acquired immunodeficiency; 9. Unwillingness to sign the informed consent form; 10. Other conditions deemed unsuitable for participation in this study by the investigator.","ALL","18 Years","75 Years",{"count":20,"type":21},193,"ESTIMATED","INTERVENTIONAL",[24],"NA","Research purpose\n\n1. To evaluate the impact of complex behavioral intervention on the one-year overall survival rate of patients with unresectable liver cancer after comprehensive treatment, a comparative study was conducted between the complex behavioral intervention group and the standard medical care control group, and the dose-response relationship between the intervention intensity and clinical outcomes was explored.\n2. Analyze the impact mechanisms of complex behavioral interventions on patients' quality of life, adverse treatment reactions, and key biological indicators, including evaluating clinical outcomes such as 2-year overall survival rate, progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR), as well as the association between changes in related biomarkers and behavioral compliance.\n3. Evaluate the implementation effect and sustainability of the \"in-hospital face-to-face + wechat platform\" hybrid intervention model, including intervention acceptance, long-term behavior maintenance, health economic benefits, and perioperative recovery of patients undergoing down-conversion surgery.",[27,28],"Primary Hepatocellular Carcinoma","Unresectable Liver Cancer","NOT_YET_RECRUITING","2026-01-04",{"date":32,"type":33},"2026-01-13","ACTUAL",{"date":35,"type":21},"2026-01",{"date":37,"type":21},"2028-12",{"name":39,"class":40},"Eastern Hepatobiliary Surgery Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100600649","29-gene-liver-cancer-subtype-and-immunotherapy-effectiveness-100600649","NCT07100236","29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness","Identification of a Novel 29-Gene-Based Subtype of Hepatocellular Carcinoma and Its Correlation With Immunotherapy Efficacy","Inclusion Criteria:\n\n* ≥18 years old.\n* Patients who visited multiple centers including Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (the leading center) and were diagnosed with primary hepatocellular carcinoma by surgical pathological histology.\n* They received targeted drug combined with immune checkpoint inhibitor treatment after the specimen collection time point (post - surgery or post - puncture) (that is: local treatments such as TACE, ablation, etc. are allowed before the start of targeted - immunotherapy combination treatment, but an interval of ≥4 weeks from the targeted - immunotherapy treatment is required).\n* Had measurable tumor lesions at the observation start point (according to RECIST 1.1 criteria), and the tumor response status (including complete response \\[CR\\], partial response \\[PR\\], stable disease \\[SD\\] or progressive disease \\[PD\\]) could be judged by imaging examination during the observation (such as post - treatment evaluation).\n* Had accessible frozen tumor tissue samples from surgical resection (sample volume ≥3g); or tumor tissue samples obtained by puncture (puncture samples need to meet the pathological diagnosis requirements, and the sample quality can support subsequent transcriptome sequencing and analysis).\n* Voluntarily participate in this study and sign the informed consent form. If the subject is unable to read and sign the informed consent form due to incapacity and other reasons, their guardian shall act as the agent for the informed process and sign the informed consent form. If the subject is unable to read the informed consent form (e.g., illiterate subject), a witness shall witness the informed process and sign the informed consent form.\n\nExclusion Criteria:\n\n* Received any local treatment during the targeted - immunotherapy combination treatment (including during treatment and within 4 weeks after treatment interruption), including:\n\nTranscatheter arterial chemoembolization (TACE), transcatheter arterial embolization (TAE), drug - eluting bead transcatheter arterial chemoembolization (DEB - TACE) and other vascular interventional therapies; Radiofrequency ablation, microwave ablation, cryoablation, laser ablation and other ablation therapies; Stereotactic body radiation therapy (SBRT), three - dimensional conformal radiation therapy, intensity - modulated radiation therapy and other local radiation therapies; Intratumoral injection therapy, high - intensity focused ultrasound (HIFU) and other local physical\u002Fchemical therapies.\n\n* Local treatment was initiated before the start of targeted - immunotherapy combination treatment, and the local treatment continued into the targeted - immunotherapy treatment period (that is, there was an overlap between local treatment and targeted - immunotherapy treatment or the interval was \\\u003C 4 weeks).\n* Complicated with other active malignant tumors (except for those with cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and papillary thyroid carcinoma with no recurrence for more than 5 years after surgery).\n* Severe impairment of important organ functions:\n\nLiver function: Child - Pugh class C, or total bilirubin \\> 3×ULN; Renal function: Serum creatinine \\> 1.5×ULN and estimated glomerular filtration rate (eGFR) \\\u003C 50ml\u002Fmin; Cardiac function: New York Heart Association (NYHA) cardiac function class Ⅲ - Ⅳ, or left ventricular ejection fraction (LVEF) \\\u003C 50%.\n\n* Had uncontrolled active infections, including:\n\nHepatitis B virus DNA \\> 2000IU\u002Fml (without receiving antiviral treatment); Hepatitis C virus RNA positive and without receiving antiviral treatment; Active tuberculosis infection, septicemia, etc.\n\n* Had a history of autoimmune diseases and currently still needed to use systemic glucocorticoids (prednisone \\> 10mg\u002Fday) or other immunosuppressive therapies.\n* Pregnant or lactating women, or patients planning to become pregnant during the study.\n* Had a definite history of allergy to the targeted drugs or immune checkpoint inhibitors involved in the study.\n* The researcher believed that there were other factors that might affect the judgment of treatment response (such as uncontrolled hypertension, coagulation dysfunction, simultaneous use of other antineoplastic drugs during targeted - immunotherapy treatment, etc.).",{"count":50,"type":21},350,"1 Year","OBSERVATIONAL","This clinical study plans to include 350 liver cancer patients from 10 tertiary hospitals nationwide, starting from August 1, 2025, at multiple centers such as the affiliated Run Run Shaw Hospital of Zhejiang University School of Medicine (the leading unit). They will be divided into a new typing queue (100 cases) and another typing queue (250 cases) using the 29 gene set algorithm. The study will collect tumor tissue samples obtained from surgical resection or puncture of patients (meeting the requirements of sample size and tumor cell proportion), perform RNA seq transcriptome sequencing, and extract patient baseline data, clinical pathological characteristics, laboratory test results, treatment information, and follow-up data from the hospital medical record system. The main objective of this study is to observe the disease progression time (TTP) and objective response rate (ORR) of patients after receiving targeted combined immunotherapy. The secondary observations include progression free survival (PFS), overall survival (OS), dynamic changes in tumor markers, liver function status, and survival after progression. The aim is to analyze the correlation between the 29 gene based new subtype of liver cancer and the efficacy of immunotherapy, providing a basis for precise diagnosis and treatment of liver cancer.",[27],[27,56,57],"Immunotherapy","RNA-seq","2025-07-27",{"date":60,"type":33},"2025-08-03",{"date":62,"type":21},"2025-08-01",{"date":64,"type":21},"2027-08-01",{"name":66,"class":40},"Junjie Xu",13,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100525612","phase-1-clinical-study-of-vg161-combined-with-camrelizumab-in-patients-with-advanced-primary-hepatocellular-carcinoma-100525612","NCT06124001","Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma","An Open-label Phase Ib\u002FIIa Clinical Trial of VG161 Combined With Camrelizumab in the Treatment of Advanced Primary Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Subjects must give informed consent to this study before the trial and voluntarily sign a written informed consent form.\n* Age 18 to 75 (inclusive), gender is not limited.\n* Patients with advanced primary hepatocellular carcinoma confirmed by histopathology or cytology.\n* According to the CSCO Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition), patients who have received at least previous first-line treatment regimens that have failed treatment (disease progression or inability to tolerate treatment) must have been treated.\n* According to RECIST 1.1, it is determined that at least one CT examination shows that it is measurable and meets the requirements of the volume of injection administration (or the volume of first injection administration in phase IIa) that can be injected under ultrasound guidance (preferably the main tumor burden lesion) under ultrasound guidance, and the longest baseline diameter of the injection lesion (short diameter of lymph node lesions) is \\>1.5 cm (of which the portal vein lymph node is short, the diameter needs to be \\> 20 mm).\n* Those with positive herpes simplex virus antibody test results (HSV-1 IgG or HSV-1 IgM).\n* ECOG physical status score 0-1.\n* Estimated survival time of more than 3 months.\n* Have adequate organ function:\n\n  1. Routine blood (no blood transfusion or colony-stimulating factor therapy within 14 days): ANC≥ 1.5×109\u002FL, PLT≥75×109\u002FL, Hb≥85g\u002FL, lymphocyte count ≥1.5×109\u002FL (for lymphocyte count 0.8×109\u002FL to 1.5×109\u002FL is determined by the investigator whether to enroll);\n  2. Liver function: TBIL≤1.5×ULN, ALT≤5×ULN, AST≤5×ULN;\n  3. Child-Pugh A or better B (≤ 7);\n  4. Renal function: Cr≤1.5×ULN, and creatinine clearance ≥ 45ml\u002Fmin (calculated according to Cockcroft-Gault formula);\n  5. Coagulation function: activated partial thromboplastin time (APTT) ≤ 1.5×ULN, international normalized ratio (INR) ≤1.5×ULN.\n* Eligible subjects of childbearing potential (male and female) must agree to use a reliable method of contraception (hormonal or barrier or abstinence) during the trial and at least 90 days after the last dose (VG161 or carrelizumab, whichever occurs later); Female patients of childbearing age must have a negative blood pregnancy test within 7 days prior to enrollment.\n\nExclusion Criteria:\n\n* Known fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma or mixed hepatocellular carcinoma.\n* Have received chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy and other anti-tumor drugs within 4 weeks before the first use of study drugs, among which oral fluorouracils and small molecule targeted drugs are the first use of study drugs. Within the first 2 weeks or the 5 half-lives of the drug (whichever is longer).\n* Have received other unmarketed clinical trial treatments within 4 weeks before using the study drug for the first time.\n* Have undergone major organ surgery (excluding puncture biopsy) or experienced significant trauma within 4 weeks before taking the study drug for the first time.\n* Patients who have received systemic corticosteroids (prednisone \\>10 mg\u002Fday or equivalent doses of similar drugs) or other immunosuppressants within 14 days before the first use of study drugs;Exceptions are the following: treatment with topical, ocular, intraarticular, intranasal, and inhaled corticosteroids; short-term use of corticosteroids (≤10 mg prednisone equivalent) for prophylactic treatment (e.g., prevention of contrast media allergy).\n* Have received vaccination within 4 weeks before the first use of study drugs.\n* Known severe allergic reaction to any monoclonal antibody.\n* The adverse reactions of previous anti-tumor treatments have not returned to CTCAE 5.0 grade ≤1 (except for toxicities such as hair loss that the researcher has judged to have no safety risks).\n* Liver tumor burden is greater than 50% of the total liver volume, or those who have received liver transplantation in the past.\n* Patients with central nervous system metastasis, spinal cord metastasis and\u002For spinal cord compression are not suitable for inclusion according to the investigator's judgment.\n* In the period of recurrent infection of herpes simplex virus, with corresponding clinical manifestations, such as cold sores, herpetic keratitis, herpetic dermatitis, genital herpes, etc.\n* Other uncontrolled active infections.\n* Have a history of immunodeficiency, including positive HIV antibody test and positive Treponema pallidum antibody test.\n* Patients with active chronic hepatitis B or active hepatitis C (except hepatitis B virus carriers, stable hepatitis B after drug treatment \\[negative HBV-DNA test or \\\u003C50IU\u002Fml\\] and cured hepatitis C patients \\[HCV RNA Tested negative\\]).\n* Have a history of serious cardiovascular and cerebrovascular diseases:\n\n  1. Ventricular arrhythmias requiring clinical intervention;\n  2. QTc interval\\>480ms;\n  3. Acute coronary syndrome, congestive heart failure, stroke or other grade III or above cardiovascular events within 6 months;\n  4. New York Heart Association (NYHA) cardiac function class ≥ class II or left ventricular ejection fraction (LVEF) \\\u003C40%;\n  5. Uncontrolled hypertension (systolic blood pressure ≥140mmHg, or diastolic blood pressure ≥90mmHg after treatment).\n* Patients with active or past autoimmune diseases that may relapse (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (including but not limited to these diseases or syndromes, etc.); but does not include patients with clinically stable autoimmune thyroiditis, autoimmune-mediated hypothyroidism treated with a stable dose of thyroid replacement hormone; Type I diabetes on insulin; patients with vitiligo or childhood asthma\u002Fallergies that have resolved and do not require any intervention in adulthood.\n* Have received immunotherapy and experienced immune-related adverse events (irAEs) such as immune-related pneumonia, myocarditis, etc., which may affect the safety of the trial medication as judged by the researcher.\n* Known alcohol or drug dependence.\n* People with mental disorders or poor compliance.\n* Pregnant or lactating women.\n* Patients with obvious symptoms and unstable pleural effusion, peritoneal effusion or pericardial effusion (those with stable clinical symptoms after treatment of pleural effusion, ascites or pericardial effusion can be included).\n* The researcher believes that the subject has other serious systemic diseases or other reasons and is not suitable to participate in this clinical study.",{"count":76,"type":21},36,[78,79],"PHASE1","PHASE2","VG161 is a recombinant human-IL12\u002F15\u002FPDL1B oncolytic HSV-1 injection.This study will be conducted in combination with camrelizumab in patients with advanced advanced primary hepatocellular carcinoma who have received at least one first-line treatment regimen. This is an open-label study divided into two parts.\n\nPart 1: This part is an escalating dose trial to explore the safety of the combination and determine the recommended safe dose of the combination.\n\nPart 2: This part is an extension trial to investigate the preliminary efficacy of the combination at a safe dose.",[27],[27],"2023-11-13",{"date":85,"type":33},"2023-11-15",{"date":87,"type":21},"2023-11-30",{"date":89,"type":21},"2026-06-30",{"name":91,"class":92},"CNBG-Virogin Biotech (Shanghai) Ltd.","INDUSTRY"]